NASDAQ:RGEN
Repligen Corporation Stock News
$171.94
+0.91 (+0.532%)
At Close: May 17, 2024
Repligen Co. (NASDAQ:RGEN) Shares Acquired by CENTRAL TRUST Co
10:42am, Monday, 06'th Dec 2021 Dakota Financial News
CENTRAL TRUST Co lifted its position in shares of Repligen Co. (NASDAQ:RGEN) by 531.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 101 shares of the biotechnology companys stock after purchasing an additional 85 shares during the quarter. CENTRAL TRUST Cos holdings []
Repligen Co. (NASDAQ:RGEN) Shares Purchased by Raymond James Trust N.A.
12:22pm, Sunday, 05'th Dec 2021 Dakota Financial News
Raymond James Trust N.A. increased its position in shares of Repligen Co. (NASDAQ:RGEN) by 9.7% in the third quarter, HoldingsChannel reports. The firm owned 1,810 shares of the biotechnology companys stock after acquiring an additional 160 shares during the quarter. Raymond James Trust N.A.s holdings in Repligen were worth $523,000 as of its most recent []
AdvisorNet Financial Inc Boosts Stake in Repligen Co. (NASDAQ:RGEN)
11:16am, Sunday, 05'th Dec 2021 Transcript Daily
AdvisorNet Financial Inc grew its stake in Repligen Co. (NASDAQ:RGEN) by 255.0% in the third quarter, HoldingsChannel reports. The institutional investor owned 710 shares of the biotechnology companys stock after buying an additional 510 shares during the period. AdvisorNet Financial Incs holdings in Repligen were worth $205,000 as of its most recent filing with the []
Atticus Wealth Management LLC Takes Position in Repligen Co. (NASDAQ:RGEN)
02:10pm, Wednesday, 01'st Dec 2021 Transcript Daily
Atticus Wealth Management LLC purchased a new position in shares of Repligen Co. (NASDAQ:RGEN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 331 shares of the biotechnology companys stock, valued at approximately $96,000. Other institutional investors and hedge funds have []
Dow Jones Dumps 900 Points On Virus Resurgence; Travel Stocks Dive; PerkinElmer, Quest, Repligen Near Buy Points
05:34pm, Friday, 26'th Nov 2021 Investor''s Business Daily
Travel stocks, oil prices and bond yields dived; Test and biotech leaders rally toward buy points.
Veriti Management LLC Has $277,000 Stock Holdings in Repligen Co. (NASDAQ:RGEN)
12:14pm, Monday, 22'nd Nov 2021 Dakota Financial News
Veriti Management LLC decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 20.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 959 shares of the biotechnology companys stock after selling 250 shares during the quarter. Veriti Management LLCs holdings in Repligen []
Anthony Hunt Sells 17,355 Shares of Repligen Co. (NASDAQ:RGEN) Stock
09:42am, Sunday, 21'st Nov 2021 Dakota Financial News
Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt sold 17,355 shares of Repligen stock in a transaction dated Thursday, November 18th. The stock was sold at an average price of $276.85, for a total value of $4,804,731.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. []
Repligen Corp (RGEN) CEO Anthony Hunt Sold $4.8 million of Shares
04:15am, Saturday, 20'th Nov 2021 GuruFocus
Related Stocks: RGEN ,
Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt Sells 17,355 Shares
10:16pm, Friday, 19'th Nov 2021 Transcript Daily
Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt sold 17,355 shares of Repligen stock in a transaction on Thursday, November 18th. The shares were sold at an average price of $276.85, for a total value of $4,804,731.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. []
Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?
11:20am, Thursday, 18'th Nov 2021 Zacks Investment Research
Style Box ETF report for RFG
Repligen Co. (NASDAQ:RGEN) Expected to Announce Quarterly Sales of $179.73 Million
06:28pm, Wednesday, 17'th Nov 2021 Transcript Daily
Analysts forecast that Repligen Co. (NASDAQ:RGEN) will report sales of $179.73 million for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Repligens earnings, with estimates ranging from $177.50 million to $181.56 million. Repligen posted sales of $108.65 million during the same quarter last year, which would indicate a positive year []
SV Health Investors, LLC Buys Repligen Corp, Sells AdaptHealth Corp, Bicycle Therapeutics PLC
07:38pm, Tuesday, 16'th Nov 2021 GuruFocus
Related Stocks: RGEN , AHCO , BCYC ,
Echo Street Capital Management LLC Buys Repligen Corp, Lightspeed Commerce Inc, Coupa Software ...
09:38pm, Monday, 15'th Nov 2021 GuruFocus
Related Stocks: RGEN , COUP , CDNS , ADSK , STNE , CP , LSPD , BL , TOST , CRL , DOCS , AFRM , AON , CNI , SQSP , BKNG , MGP , PHR ,
Repligen Corporation to Present at Upcoming Investor Conferences
07:30am, Friday, 12'th Nov 2021
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at tw
Repligen (RGEN) Q3 Earnings and Sales Beat, 2021 View Up
12:59pm, Friday, 29'th Oct 2021
Repligen's (RGEN) third-quarter earnings and revenues beat estimates. The company raises its guidance for 2021.